Tracked worldwide shippingCard and crypto checkoutSealed, lyophilised vialsFor research use only. Not for human or veterinary consumption.Tracked worldwide shippingCard and crypto checkoutSealed, lyophilised vialsFor research use only. Not for human or veterinary consumption.
DBRLABS

Eloralintide vs Retatrutide: How the Two Lilly Drugs Compare

Eloralintide vs retatrutide side by side: amylin agonist vs GIP/GLP-1/glucagon triple agonist, 20.1% vs 24.2% weight loss at 48 weeks in phase 2, side effects and approval timing.

Updated 8 November 2026 7 min read 10 primary sources

Key facts

  • Eloralintide is a selective amylin receptor agonist. Retatrutide is a GIP, GLP-1 and glucagon receptor triple agonist. Both are once-weekly Lilly injections.[1][5]
  • Phase 2, 48 weeks: eloralintide 20.1% at 9 mg vs retatrutide 24.2% at 12 mg mean weight loss.[1][5]
  • Retatrutide is further along: phase 3 TRIUMPH-1 reported 28.3% at 80 weeks, and Lilly plans an FDA filing in Q1 2027.[6][8]
  • Eloralintide phase 3 (ENLIGHTEN) has first completions estimated for 2028.[10]
  • Heart rate moves in opposite directions in early data: down with eloralintide in phase 1, up (dose-dependent, peaking at week 24) with retatrutide in phase 2.[4][5]

What Is the Difference Between Eloralintide and Retatrutide?

The main difference is the target: eloralintide activates amylin receptors only, while retatrutide activates three incretin and glucagon receptors (GIP, GLP-1 and glucagon).[3][5]

FeatureEloralintideRetatrutide
DeveloperEli LillyEli Lilly
ReceptorsAmylin (selective for AMY1R)GIP, GLP-1 and glucagon
DosingOnce weekly, under the skinOnce weekly, under the skin
Best phase 2 result (48 wk)-20.1% (9 mg)[1]-24.2% (12 mg)[5]
Best phase 3 resultNo results yet-28.3% at 80 wk, TRIUMPH-1[6]
Stage (Nov 2026)Phase 3 runningPhase 3 reported, filing planned Q1 2027[8]

Eloralintide vs Retatrutide Weight Loss

In separate 48-week phase 2 trials, eloralintide 9 mg gave 20.1% mean weight loss and retatrutide 12 mg gave 24.2%, so retatrutide was about 4 points ahead at its top dose.[1][5]

Mean weight loss at 48 weeks, separate phase 2 trials
Eloralintide 3 mg12.4%Eloralintide 6 mg17.6%Eloralintide 9 mg20.1%Retatrutide 4 mg17.1%Retatrutide 8 mg22.8%Retatrutide 12 mg24.2%

Not a head-to-head trial. Eloralintide: n = 263, efficacy estimand. Retatrutide: n = 338, least-squares mean. Sources: Lilly 6 Nov 2025; Jastreboff et al., NEJM 2023.

Retatrutide’s phase 3 trials then went further: 28.3% at 80 weeks in TRIUMPH-1 (12 mg) and 28.7% at 68 weeks in TRIUMPH-4 (12 mg), against about 2% on placebo.[6][7]

These are different trials with different people, so the gap is a rough guide, not a measured difference. No trial has compared eloralintide and retatrutide directly.

Side Effects Compared

Both cause mainly gastrointestinal side effects that rise with dose; eloralintide’s phase 2 nausea ranged from 11% at 1 mg to 64% at 6 mg (placebo 14%), and retatrutide’s GI events were also dose-related.[2][5]

  • Eloralintide phase 2: fatigue reached 43% to 46% in the higher-dose arms, against 12% on placebo. Lilly says slower dose escalation lowered these effects.[2][1]
  • Eloralintide phase 1: pulse fell by up to 14.4 beats per minute at 12 mg.[4]
  • Retatrutide phase 2: dose-dependent heart rate increases peaked at week 24 and then declined.[5]
  • Details: eloralintide side effects.

Can Eloralintide and Retatrutide Be Combined?

No eloralintide plus retatrutide trial has been registered; Lilly’s combination programme pairs eloralintide with tirzepatide (EloraTZP).[9]

EloraTZP reached 23.3% weight loss at 48 weeks in people with type 2 diabetes. See eloralintide vs tirzepatide.[9]

Which Will Be Available First?

Retatrutide will come first: Lilly plans to file it with the FDA in Q1 2027, while eloralintide’s phase 3 trials are not expected to complete before 2028.[8][10]

Frequently Asked Questions

Is eloralintide better than retatrutide?

On published numbers, retatrutide produced more weight loss: 24.2% at 48 weeks in phase 2 against 20.1% for eloralintide, and up to 28.7% in phase 3. The two have never been tested against each other in one trial.

Is eloralintide stronger than retatrutide?

No. At the top doses tested so far, retatrutide has shown larger average weight loss. Eloralintide works on a different pathway (amylin), which is why Lilly is testing it in combinations.

Are eloralintide and retatrutide made by the same company?

Yes. Both are developed by Eli Lilly.

Can you take eloralintide with retatrutide?

There is no clinical trial of the two together. Neither drug is approved, and nothing here is medical advice.

Sources

  1. Eli Lilly press release, 6 Nov 2025: eloralintide phase 2 results
  2. Billings LK, et al. Eloralintide phase 2, 48-week trial. The Lancet 2025;406:2631-2643. DOI 10.1016/S0140-6736(25)02155-5
  3. Briere DA, et al. Discovery and first-in-human study of eloralintide. Molecular Metabolism 2025;102:102271. DOI 10.1016/j.molmet.2025.102271
  4. Bhattachar S, et al. Eloralintide 12-week multiple-dose phase 1. Diabetes, Obesity and Metabolism 2026;28(4):2651-2660. DOI 10.1111/dom.70439
  5. Jastreboff AM, et al. Retatrutide phase 2. N Engl J Med 2023;389:514-526. DOI 10.1056/NEJMoa2301972
  6. Eli Lilly press release, 21 May 2026: retatrutide TRIUMPH-1 phase 3
  7. Eli Lilly press release, 11 Dec 2025: retatrutide TRIUMPH-4 phase 3
  8. Eli Lilly press release, 23 Jul 2026: retatrutide TRIUMPH-2 and TRIUMPH-3
  9. Eli Lilly press release, 30 Sep 2026: EloraTZP (eloralintide + tirzepatide) phase 2b results
  10. ClinicalTrials.gov NCT07321886, ENLIGHTEN-1

For research use only. Not for human or veterinary consumption. This guide summarises published research for information only. It is not medical advice and does not describe any use of products sold on this site.

Related Guides

Comparisons

Eloralintide vs Tirzepatide, and the EloraTZP Combination

Eloralintide vs tirzepatide (Zepbound, Mounjaro): amylin vs GIP/GLP-1, 20.1% at 48 weeks vs 20.9% at 72 weeks, and EloraTZP, the combination that reached 23.3% in type 2 diabetes.

Comparisons

Eloralintide vs Cagrilintide: Two Amylin Analogues Compared

Eloralintide vs cagrilintide: Lilly’s selective amylin agonist vs Novo Nordisk’s non-selective one. Receptor selectivity, half-life, 20.1% vs 10.8% weight loss, CagriSema and amycretin.

Trials

Eloralintide Clinical Trial Results: Phase 1, Phase 2 and Phase 3

Every eloralintide trial result to date: up to 20.1% weight loss at 48 weeks in phase 2, the EloraTZP combination at 23.3%, and the six ENLIGHTEN phase 3 trials due from 2028.